Evidence map›Paper›PMID 30224292›Full record

ArticleAnnals of epidemiology2018

Progress and pitfalls in measuring HIV preexposure prophylaxis coverage in the United States.

Eli S Rosenberg, Julia L Marcus

Abstract readEditorial
In one paragraph

Article in Annals of epidemiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Association of Race and Other Social Determinants of Health With HIV Pre-Exposure Prophylaxis Use: A County-Level Analysis Using the PrEP-to-Need Ratio.AIDS education and prevention : official publication of the International Society for AIDS Education · 2022
    Article
  6. Article
  7. Article
  8. Has Pre-exposure Prophylaxis Made a Difference at a Population Level? Jury Is Still Out.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020
    Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Eli S RosenbergDepartment of Epidemiology and Biostatistics, University at Albany School of Public Health, SUNY, Rensselaer, NY. Electronic address: erosenberg2@albany.edu.
Julia L MarcusDepartment of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA.

Funding

Understanding substance use and incident HIV/STI among young black MSMR01DA038196 · NIDA · EMORY UNIVERSITY · PI ROSENBERG, ELI SAMUEL, SULLIVAN, PATRICK SEAN · 2014 to 2018
$3.2M
ENHANCING MODELS OF HIV, VIRAL HEPATITIS, STIs, AND TUBERCULOSIS TO INFORM AND IMPROVE PUBLIC HEALTH IMPACTU38PS004646 · PS · EMORY UNIVERSITY · PI SULLIVAN, PATRICK · 2014 to 2015
$2.9M
Optimizing Care for HIV/HCV-Coinfected Patients in the New HCV Treatment EraK01AI122853 · NIAID · KAISER FOUNDATION RESEARCH INSTITUTE · PI MARCUS, JULIA L. · 2016 to 2020
$655k
NCHHSTP CDC HHS U38 PS004646NIAID NIH HHS K01 AI122853NIDA NIH HHS R01 DA038196
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdultAnti-HIV AgentsEmtricitabine, Tenofovir Disoproxil Fumarate Drug CombinationFemaleHIV InfectionsHumansMaleMiddle AgedPre-Exposure ProphylaxisUnited StatesAnti-HIV AgentsEmtricitabine, Tenofovir Disoproxil Fumarate Drug Combination

Identifiers

PMID30224292
PMCPMC6417495

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.